FMR1 and fragile X syndrome: I think there is a strong confluence of data building in preclinicalstudies for phosphodiesterase inhibitors that work on the reducedcyclic AMP production seen in animal models and people with FXS, aswell as preclinical evidence that agents acting on ion channels regulatedby FMRP may provide good therapeutic benefit.